^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS G12C

    i
    Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    1d
    HCRN LUN23-618: Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases (clinicaltrials.gov)
    P2, N=30, Recruiting, Ryan Gentzler, MD | Trial completion date: Aug 2028 --> Feb 2028 | Trial primary completion date: Mar 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Krazati (adagrasib)
    1d
    Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=91, Terminated, Deciphera Pharmaceuticals, LLC | Phase classification: P1/2 --> P1 | N=144 --> 91 | Trial completion date: Aug 2028 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2027 --> Mar 2026; Trial terminated due to business decision, not based on any safety or efficacy concerns.
    Phase classification • Enrollment change • Trial completion date • Trial termination • Trial primary completion date • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • BRAF V600K • KRAS G12
    |
    Mekinist (trametinib) • Lumakras (sotorasib) • Mektovi (binimetinib) • inlexisertib (DCC-3116)
    1d
    RMC-6291-001: Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=222, Active, not recruiting, Revolution Medicines, Inc. | Trial completion date: Dec 2025 --> Sep 2027 | Trial primary completion date: Nov 2024 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C
    |
    elironrasib (RMC-6291)
    3d
    Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients (clinicaltrials.gov)
    P=N/A, N=102, Completed, Amgen | Recruiting --> Completed | Trial completion date: Jun 2026 --> Dec 2025
    Trial completion • Trial completion date • HEOR • Real-world evidence
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib)
    4d
    Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Emory University | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Mar 2028 --> Mar 2029
    Trial completion date • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS G12C • KRAS G12
    |
    Opdivo (nivolumab) • Avmapki (avutometinib) • Fakzynja (defactinib) • ABP 206 (nivolumab biosimilar)
    4d
    SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC. (PubMed, Future Oncol)
    www.clinicaltrials.gov identifier is NCT06119581. EudraCT: 2023-503412-33-00.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • olomorasib (LY3537982)
    4d
    Clinical Concordance of Pan Lung Cancer PCR Panel Covering 167 Actionable Variants Across 11 Genes and Other Validated Assays in the LC-SCRUM-Asia Registry. (PubMed, JTO Clin Res Rep)
    The Pan Lung Cancer PCR Panel was highly concordant with other assays. The panel can be performed in local laboratories with a rapid turnaround time and represents an attractive alternative to next-generation sequencing for patients with lung cancer.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • EGFR mutation • KRAS G12C • BRAF mutation • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • KRAS G12 • NTRK fusion
    |
    Oncomine™ Dx Target Test
    7d
    Active fragment assembly strategy enabling fast discovery of KRAS inhibitors against pancreatic cancer cells. (PubMed, Eur J Med Chem)
    Additionally, molecular docking studies demonstrate a robust binding affinity of compound 10b with both KRASG12C and KRASG12D proteins. These findings provided unique pathways for investigating multi-target inhibitors aimed at mutated KRAS proteins, thereby advancing the development of innovative molecular therapies for cancers associated with KRAS mutations.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12
    7d
    Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Nov 2026 | Trial primary completion date: Mar 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • carfilzomib
    7d
    Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. (PubMed, Lancet Oncol)
    In treatment-naive KRASG12C-mutated NSCLC, fulzerasib plus cetuximab showed encouraging activity with a favourable safety profile. The combination is currently being planned for investigation in a phase 3 study.
    P1/2 data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • Dupert (fulzerasib)
    8d
    Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers (clinicaltrials.gov)
    P1, N=52, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2030 --> Dec 2026
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • KEAP1 (Kelch Like ECH Associated Protein 1) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    KRAS mutation • KRAS G12C • KEAP1 mutation • KRAS G12
    |
    Lynparza (olaparib) • Krazati (adagrasib)
    9d
    KANDLELIT-013: MK-3475A±MK-1084 in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) (clinicaltrials.gov)
    P3, N=400, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • calderasib (MK-1084)